Clinuvel Pharmaceuticals (CLVLY)

[FarmaZutical]

4C out

http://www.asx.com.au/asxpdf/20170731/pdf/43l021w2gbhj0d.pdf

$6.247.000in receipts vs $1.235.000 last 2nd quarter.

$23m in the bank. Impressive.

Overall very good given the fact that last quarter ought to be off season. Next quarter will be even better.
With cash on hand and the current results we ought to be at minimum $10 per share today. Also add NDA approval within the next year or so and further roll out in Europe.

Their communication sucks and they are very much behind schedule but the product is a winner.

Comments from the reputable poster, Frogster of SS (copy / pasted):

In Reply To: ajshare's post @ Yesterday, 07:30 PM

Happy to see those numbers. They're great versus my expectations. After the disappointment of the previous quarter I was only looking at A$4m receipts. Happy to be wrong this time.

Couple of comments from other lines items:

-Cash generation was strong on these receipts, helped by corporate costs nearly A$0.4m below guidance - my guess is this might be an exchange rate effect (more on this in a minute) - and also by production costs being also nearly A$0.4m below guidance. Even if these items weren't flattering, I'd be pleased to see the cash generation. It's still better than I thought it'd be.

-After a few quarters of very low R&D spend, the current quarter will be ramped up a little again to A$0.15m. Scenesse Enfance/Goat thing spending ramping up? They also spent nearly 4 times more in the reported quarter than predicted (prediction was only A$0.02m).

-Production costs for the current quarter are expected to be A$0.7m. I find it a little tricky to interpret this. They were expecting A$1m for the quarter just reported, and it was only A$0.6m. Does this mean they are already stocked up for peak seasonal demand? Does it mean peak demand is going to weaker than previously thought? Does it mean they're just getting better at forecasting this cost (they've been way off a number of times now). Time will tell, but my guess is a combination of these 3 factors.

-I wouldn't be surprised if we see a corrected version of this 4C published. Item 4 in it seems to have arithmetic/presentation errors. Item 4.2 suggests A$4.626m was USED in operating activities rather than was GENERATED by it, and Item 4.5 suggests exchange rate movements consumed A$0.375 rather than inflating balances as suggested by the difference listed at year end (28) versus that at the 9m stage (403). If they have listed the sense of these movements correctly, then the cash at the end of period should be 18772-4626-21-375=13750. Given they have a bank balance of A$14.339m this cannot be right and must simply be an error!